The clients were planning to launch a new therapy in oncology, and they needed a full global value dossier to demonstrate the health and economic value provided by their treatment compared with the available treatment landscape. This dossier would also prove essential for gaining market access for their therapy. The cost-effectiveness model for the global value dossier would need to be informed with the appropriate inputs in order to generate robust estimates and provide a reliable basis for decision-making.
A network meta-analysis was performed to produce relative effects information on multiple endpoints for all treatments of interest. To provide well-founded estimates, the main challenge was to perform a feasibility assessment and determine which studies were sufficiently comparable to the clinical trial of interest for use in our network meta-analysis.